Innoquest
Innoquest Pathology is Malaysia's largest private multidisciplinary clinical diagnostic laboratory, serving 4,000+ GPs and 65 hospitals across 85+ facilities with digital histopathology, molecular diagnostics, and routine testing, operating as a subsidiary of Pathology Asia Group.
- Company typePrivate
- Founded1996
- HeadquartersPetaling Jaya, Malaysia
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Innoquest does
Innoquest Pathology Sdn. Bhd. (formerly Gribbles Pathology) is Malaysia's largest private clinical diagnostic laboratory, operating as a subsidiary of Pathology Asia Group. Founded in 1996 and headquartered in Petaling Jaya, the company was formed through the successive mergers of Gribbles Pathology, Quantum Diagnostics (2019), and Clinipath Malaysia (2021), and rebranded under the unified Innoquest name in May 2022. It is the only multidisciplinary clinical laboratory in Malaysia holding both College of American Pathologists (CAP) and MS ISO 15189 accreditations.
The company operates over 85 electronically-linked pathology facilities across Peninsular Malaysia, Sabah, and Sarawak, supported by 1,200+ staff including 20+ in-house pathologists, and processes more than 4 million patient episodes annually. Its technology stack combines digital histopathology with whole-slide imaging, AI-powered imaging algorithms, and a telepathology platform for remote expert consultation, alongside molecular diagnostics platforms such as multiplex PCR (QIAstat-Dx), methylation-specific PCR (COLOTECT), immunoblotting (107-allergen panel), and automated urine culture (Alifax Alfred AST60). Clinician-facing digital tools — the BioMark-powered e-Results portal, e-Ordering system, consumables e-commerce, and chronic disease management modules — anchor the service workflow.
Innoquest generates revenue through B2B diagnostic testing services billed to clinicians, hospitals, and medical centres, with results delivered via e-portal, CRM transmission, or physical courier. Distribution is driven by dedicated Key Account Executives managing relationships with approximately 4,000 GPs and 65 hospitals, supplemented by daily courier specimen pickup, on-site screening services, and Continuing Medical Education programs targeting healthcare professionals. Pricing is not publicly disclosed and is negotiated with registered institutional accounts; the model functions as recurring volume-based testing revenue rather than transactional retail sales.
Innoquest firmographics
Firmographics- Name
- Innoquest
- Legal name
- Innoquest Pathology Sdn. Bhd.
- Website
- https://innoquest.com.my
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Innoquest Pathology is Malaysia's largest private multidisciplinary clinical diagnostic laboratory, serving 4,000+ GPs and 65 hospitals across 85+ facilities with digital histopathology, molecular diagnostics, and routine testing, operating as a subsidiary of Pathology Asia Group.
- Ownership category
- akta.pro rank
Innoquest industry classification
Industry- Product category
- Clinical Diagnostic Laboratory Services
- NAICS
- Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)
- akta.pro secondary industries
- Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA), Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where Innoquest is headquartered
LocationHeadquarters
- HQ city
- Petaling Jaya
- HQ country
- Malaysia
- HQ region
- Asia
Offices2 records
Markets served
Innoquest business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Clinical Laboratory Diagnostic Testing Services: Core revenue stream from providing comprehensive diagnostic testing services across haematology, microbiology, biochemistry, molecular pathology, and anatomical pathology. Services delivered to clinicians, hospitals, and medical centres with results delivered via e-portal, CRM transmission, or physical courier.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Clinical diagnostic testing services for registered healthcare providers |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Innoquest product offering
Product offeringCore offering
Innoquest Pathology operates a multi-disciplinary clinical laboratory platform providing diagnostic testing services across anatomical pathology, digital histopathology, haematology, microbiology, biochemistry, molecular diagnostics, allergy screening, infectious disease panels and cancer screening. Services are delivered to clinicians, hospitals and medical centres through 85+ electronically-linked facilities, supported by dedicated courier specimen pickup, phlebotomy, on-site workplace screening and a proprietary BioMark electronic results/ordering platform.
Product overview
Innoquest Pathology is Malaysia's largest private diagnostic laboratory services provider, operating as a unified multidisciplinary clinical laboratory platform. The offering centers on a comprehensive diagnostic testing portfolio spanning anatomical pathology (including digital histopathology with AI-powered imaging), clinical pathology disciplines (haematology, microbiology, biochemistry, molecular diagnostics), and specialized tests including allergy screening (Extensive 107), infectious disease testing (QIAstat-Dx syndromic panels, QuantiFERON-TB, Urea Breath Test), cancer screening (COLOTECT), and urine culture analysis (Alifax Alfred AST60). The platform is augmented by proprietary digital tools including the BioMark-powered e-Results Portal and e-Ordering System, complemented by operational services such as courier pickup, phlebotomy, and on-site screening. The company also provides Continuing Medical Education programs for clinician customers. With over 85 facilities and capacity for 4+ million patient episodes annually, the portfolio functions as an integrated laboratory ecosystem rather than discrete standalone products.
Differentiator
Problem solved
Functional benefit
Brands
- BioMark: Proprietary IT platform for e-results, e-ordering, and electronic records offering document portal and app features including chronic disease management tools.
Products and services
- Laboratory Diagnostic Services Comprehensive multi-disciplinary clinical laboratory testing across haematology, microbiology, biochemistry, molecular diagnostics and anatomical pathology, performing over 4 million patient episodes annually across 85+ facilities for clinicians and hospitals.
- Digital Histopathology Services State-of-the-art digital histopathology service using whole-slide imaging to convert tissue samples into high-resolution digital slides for AI-assisted analysis and remote pathologist review via telepathology.
- QIAstat-Dx Syndromic Testing Multiplex PCR syndromic testing panel providing rapid detection of respiratory (22 targets), gastrointestinal (24 targets) and meningitis/encephalitis (15 targets) infections with results delivered in under 3 hours.
- QuantiFERON-TB Gold Plus (QFT-Plus) Blood test for tuberculosis detection using Interferon Gamma Release Assay (IGRA) technology with CD8+ and CD4+ T cell response measurement, achieving >95% sensitivity and unaffected by BCG vaccination.
- Urea Breath Test (13C-Urea) Gold standard non-invasive in-vivo breath test for Helicobacter pylori detection using 13C-urea measurement of CO2 ratio changes to diagnose peptic ulcer disease and gastritis.
- Extensive 107 Allergens Test In-vitro allergy screening using immunoblotting to measure allergen-specific IgE concentrations across 107 allergens including pollens, dust mites, moulds, foods, venoms and CCD, reported in 91 items from 100µL of serum.
- COLOTECT Faecal DNA Test Non-invasive faecal DNA screening test for early colorectal cancer detection using three methylation biomarkers (SDC2, ADHFE1, PPP2R5C) with multiplex methylation-specific PCR technology achieving 88% sensitivity.
- Alifax Alfred AST60 Urine Culture Analysis Liquid-based urine culture analysis using the Alifax Alfred AST60 analyser with light-scattering technology, 60-sample batch capacity, up to 480 samples per day potential throughput and 8-12 hour turnaround for negative results.
- Courier Specimen Pickup Services Daily courier pickup of specimens from clinics, hospitals and medical centres with online scheduling via sample pickup form; service centred on Klang Valley and expanding nationwide across Malaysia.
- Phlebotomy Services Blood specimen collection services performed by trained phlebotomists to ensure optimal sample quality and quantity for downstream laboratory testing.
- On-Site Health Screening Mobile preventive health screening service delivered at workplaces and communities, providing convenient specimen collection and health assessment programmes.
Quantifiable outcome
- Reduced histopathology turnaround time from one week to 1-2 working days at Sabah facility
- +4 more outcomes
Companies that use Innoquest
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Innoquest technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature9 records
Innoquest partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Jesselton Medical CentrecoreInnoquest Pathology partnered with Jesselton Medical Centre in Kota Kinabalu, Sabah, to launch the region's first state-of-the-art digital histopathology laboratory. The facility leverages Innoquest's digital pathology, AI imaging, and telepathology capabilities. The partnership enables processing of over 400 cases monthly with results delivered in 1-2 working days, significantly advancing diagnostic healthcare in East Malaysia.
- AIA MalaysiaminorAIA Malaysia partnered with DOC2US to provide virtual health services and wellness programmes. As a clinical laboratory partner within the broader healthcare ecosystem, Innoquest's diagnostic services support such insurance and wellness initiatives.
Scale indicators7 records
Recent moves8 records
Expansion highlights4 records
Innoquest competitors and assessment
Company assessmentBroad incumbents
- Labcorp: Global clinical laboratory and diagnostics company offering comparable test menu breadth across routine and esoteric testing; relevant as a global comparable for Innoquest's scale-up trajectory.
- KPJ Healthcare: Malaysia's largest homegrown private hospital chain with significant captive diagnostic laboratory capacity across its network; competes for the same hospital and physician referral pool as Innoquest.
- Sonic Healthcare: Global clinical laboratory operator with extensive APAC presence; relevant as a comparable business model and potential future regional entrant into Malaysia's diagnostics market.
- Quest Diagnostics: U.S. clinical laboratory leader and the benchmark for scaled multi-disciplinary diagnostic operations; comparable in test menu breadth and B2B clinician focus, and a potential regional expansion competitor.
- Eurofins Scientific: Global testing services group with significant clinical diagnostics and specialty laboratory operations across Asia; comparable in multi-disciplinary, technology-enabled diagnostics delivery.
- Synlab: Europe's largest clinical laboratory services provider with a multi-country hub-and-spoke model closely analogous to Innoquest's 85-facility Malaysian network.
Direct peers
- BP Healthcare: One of Malaysia's largest private diagnostic and health screening chains, operating a multi-disciplinary laboratory and outpatient network directly competing with Innoquest for clinician referrals and patient screening volume.
- Pantai Premier Pathology (IHH Healthcare): Hospital-owned pathology arm of IHH Healthcare's Pantai network, competing directly for the same hospital referral and outpatient diagnostic testing volumes in Malaysia.
Regional players
- Bangkok Dusit Medical Services (BDMS): Thailand's largest private hospital group with significant in-house pathology operations; closely comparable multi-disciplinary clinical laboratory and hospital-integrated diagnostics model in the Southeast Asian region.
Others
- Doctor Anywhere: Regional digital health platform operating in Southeast Asia (including Malaysia) — adjacent ecosystem participant that increasingly integrates with diagnostic lab partners like Innoquest for sample collection and result delivery.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Innoquest social profiles
Digital presenceInnoquest financial estimates
Financial estimateRevenue estimate
Valuation estimate
Innoquest leadership team
Management profileNumber of profiles
Profiles3 records
Innoquest subsidiaries and ownership
Company hierarchySubsidiaries2 records
Innoquest funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Innoquest M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Innoquest
What does Innoquest do?
Innoquest Pathology operates a multi-disciplinary clinical laboratory platform providing diagnostic testing services across anatomical pathology, digital histopathology, haematology, microbiology, biochemistry, molecular diagnostics, allergy screening, infectious disease panels and cancer screening. Services are delivered to clinicians, hospitals and medical centres through 85+ electronically-linked facilities, supported by dedicated courier specimen pickup, phlebotomy, on-site workplace screening and a proprietary BioMark electronic results/ordering platform.
Is Innoquest a public or private company?
Innoquest is a private company. It is classified as corporate owned and is currently operating.
When was Innoquest founded?
Innoquest was founded in 1996. It employs 1,001 to 5,000 people.
Where is Innoquest based?
Innoquest is headquartered in Petaling Jaya, Malaysia, in the Asia region.
How does Innoquest make money?
One revenue line is on record: clinical Laboratory Diagnostic Testing Services.
Who are Innoquest's main competitors?
Broad incumbents on record are Labcorp, KPJ Healthcare, Sonic Healthcare, Quest Diagnostics, Eurofins Scientific and Synlab. Direct peers are BP Healthcare and Pantai Premier Pathology (IHH Healthcare). Bangkok Dusit Medical Services (BDMS) is listed as a regional player. Doctor Anywhere is listed as an others.
Does Innoquest have an API?
No public API is recorded for Innoquest.
What industry is Innoquest in?
Innoquest's product category is Clinical Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAFAMAB, Clinical Chemistry & Immunoassay Laboratories, with a secondary code of HLAFAMAA, Anatomic Pathology (Histopathology & Cytopathology). Its NAICS code is 62151 and its SIC code is 8071.